BIOMAT Database Logo BIOMAT Database Logo

The pharmacokinetics of a microemulsion formulation of cyclosporine in primary renal allograft recipients. The Neoral Study Group. 1996

G Barone, and C T Chang, and M G Choc, and J B Klein, and C L Marsh, and J A Meligeni, and D I Min, and M D Pescovitz, and R Pollak, and T L Pruett, and J B Stinson, and J S Thompson, and E Vasquez, and T Waid, and D G Wombolt, and R L Wong
Department of Vascular and Transplant Surgery, University of Arkansas, Little Rock 72205-7199, USA.

This study was a randomized, double-blind, 12-week comparison of the pharmacokinetics, safety, and tolerability of two cyclosporine (CsA) formulations, cyclosporine emulsion capsules and oral solution for microemulsion and cyclosporine, in the postoperative management of renal transplant patients. Of the 101 patients, aged 18 to 65, who entered the study, 89 were evaluable for pharmacokinetics. Initial dosage was 10 mg/kg per day, administered twice daily in two equal doses. Dosages were adjusted to achieve target CsA concentrations. The pharmacokinetic (PK) parameters (dose-normalized) of greatest interest were maximum blood concentration (C(max)/dose), time to reach maximum concentration (t(max), area under the blood concentration-vs.-time curve (AUC/dose), and trough blood concentrations (Co h/dose). The relative CsA bioavailabilty was found to be significantly enhanced with cyclosporine emulsion compared with cyclosporine with a 16% to 31% increase in AUC and a 32% to 42% increase in C(max). Intrapatient variability of PK parameters was significantly lower with cyclosporine emulsion than with cyclosporine for AUC, C(oh), t(max), and C(max) in many instances. This indicates a more consistent, rapid, and more complete total absorption of CsA. Despite higher CsA C(max) levels and AUCs with cyclosporine emulsion, safety and tolerability (detailed in a parallel report) were comparable to those of cyclosporine. The PK advantages of cyclosporine emulsion over cyclosporine are either independent of food conditions or possibly reflective of more consistent absorption of CsA with cyclosporine emulsion. The findings suggest that de novo use of cyclosporine emulsion may simplify and improve management of organ transplant recipients and that the PK advantages of cyclosporine emulsion may translate into clinical benefits.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007206 Individuality Those psychological characteristics which differentiate individuals from one another. Individual Differences,Difference, Individual,Differences, Individual,Individual Difference
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002626 Chemistry, Pharmaceutical Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use. Medicinal Chemistry,Chemistry, Pharmaceutic,Pharmaceutic Chemistry,Pharmaceutical Chemistry,Chemistry, Medicinal
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004655 Emulsions Colloids formed by the combination of two immiscible liquids such as oil and water. Lipid-in-water emulsions are usually liquid, like milk or lotion. Water-in-lipid emulsions tend to be creams. The formation of emulsions may be aided by amphiphatic molecules that surround one component of the system to form MICELLES. Emulsion
D005260 Female Females

Related Publications

G Barone, and C T Chang, and M G Choc, and J B Klein, and C L Marsh, and J A Meligeni, and D I Min, and M D Pescovitz, and R Pollak, and T L Pruett, and J B Stinson, and J S Thompson, and E Vasquez, and T Waid, and D G Wombolt, and R L Wong
Safety and tolerability of cyclosporine microemulsion versus cyclosporine: two-year data in primary renal allograft recipients: a report of the Neoral Study Group.
March 1997, Transplantation,
G Barone, and C T Chang, and M G Choc, and J B Klein, and C L Marsh, and J A Meligeni, and D I Min, and M D Pescovitz, and R Pollak, and T L Pruett, and J B Stinson, and J S Thompson, and E Vasquez, and T Waid, and D G Wombolt, and R L Wong
Pharmacokinetics of oral cyclosporine microemulsion formulation (Neoral) in children awaiting renal transplantation.
August 1998, Transplantation proceedings,
G Barone, and C T Chang, and M G Choc, and J B Klein, and C L Marsh, and J A Meligeni, and D I Min, and M D Pescovitz, and R Pollak, and T L Pruett, and J B Stinson, and J S Thompson, and E Vasquez, and T Waid, and D G Wombolt, and R L Wong
Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation.
April 1994, Transplantation,
G Barone, and C T Chang, and M G Choc, and J B Klein, and C L Marsh, and J A Meligeni, and D I Min, and M D Pescovitz, and R Pollak, and T L Pruett, and J B Stinson, and J S Thompson, and E Vasquez, and T Waid, and D G Wombolt, and R L Wong
The safety and tolerability of cyclosporine emulsion versus cyclosporine in a randomized, double-blind comparison in primary renal allograft recipients. The Neoral Study Group.
March 1996, Transplantation,
G Barone, and C T Chang, and M G Choc, and J B Klein, and C L Marsh, and J A Meligeni, and D I Min, and M D Pescovitz, and R Pollak, and T L Pruett, and J B Stinson, and J S Thompson, and E Vasquez, and T Waid, and D G Wombolt, and R L Wong
Cyclosporine pharmacokinetics in renal allograft recipients with diabetes mellitus with Sandimmune and Sandimmune Neoral.
December 1996, Transplantation proceedings,
G Barone, and C T Chang, and M G Choc, and J B Klein, and C L Marsh, and J A Meligeni, and D I Min, and M D Pescovitz, and R Pollak, and T L Pruett, and J B Stinson, and J S Thompson, and E Vasquez, and T Waid, and D G Wombolt, and R L Wong
A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group.
December 1996, Transplantation,
G Barone, and C T Chang, and M G Choc, and J B Klein, and C L Marsh, and J A Meligeni, and D I Min, and M D Pescovitz, and R Pollak, and T L Pruett, and J B Stinson, and J S Thompson, and E Vasquez, and T Waid, and D G Wombolt, and R L Wong
Pharmacokinetics of a microemulsion formulation of cyclosporine in pediatric liver transplant recipients.
August 1996, Transplantation proceedings,
G Barone, and C T Chang, and M G Choc, and J B Klein, and C L Marsh, and J A Meligeni, and D I Min, and M D Pescovitz, and R Pollak, and T L Pruett, and J B Stinson, and J S Thompson, and E Vasquez, and T Waid, and D G Wombolt, and R L Wong
Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Neoral Study Group.
August 1996, Transplantation proceedings,
G Barone, and C T Chang, and M G Choc, and J B Klein, and C L Marsh, and J A Meligeni, and D I Min, and M D Pescovitz, and R Pollak, and T L Pruett, and J B Stinson, and J S Thompson, and E Vasquez, and T Waid, and D G Wombolt, and R L Wong
Neoral: a microemulsion cyclosporine.
March 1996, Journal of transplant coordination : official publication of the North American Transplant Coordinators Organization (NATCO),
G Barone, and C T Chang, and M G Choc, and J B Klein, and C L Marsh, and J A Meligeni, and D I Min, and M D Pescovitz, and R Pollak, and T L Pruett, and J B Stinson, and J S Thompson, and E Vasquez, and T Waid, and D G Wombolt, and R L Wong
Cyclosporine microemulsion formulation (Neoral) in transplantation: pharmacokinetic/pharmacodynamic relationships.
August 1998, Transplantation proceedings,
Copied contents to your clipboard!